Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function

	AASLD 2025 Nov 7-11 Wash DC Parag Kumar, Wildaliz Nieves, David Z Pan, Jack Chang, Steve Tseng, Yuejiao Jiang, Yehong Wang, Ann Qin, Teckla Akinyi, Renee-Claude Mercier Gilead Sciences, Inc., Foster City, CA, USA